Moreover, the findings remained robust in additional sensitivity analyses in which the included trials were limited to trials with OS as the primary or coprimary end point, trials examining PDCD1 or PDCD1 ligand 1 inhibitors, phase 3 trials, trials examining only NSCLC, trials examining only melanoma, trials examining only cancers other than NSCLC and melanoma, first-line trials, and second-line or beyond trials (eTable 4 in the Supplement). This evidence concerns the gene PDCD1 and melanoma.